laboratory specialized in the treatment of rare neurological diseases
  • [Corporate] Home Banner

About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

Theranexus announces appointment of Mathieu Charvériat as Board of Directors Chairman 

11/03/2024 8am CET
Download PDF File (<1 Mo)

Theranexus publishes its cash position as of December 31st 2023 and presents an update on its programs 

Download PDF File (<1 Mo)

Highly Promising 12-month results in the Phase I/II trial of Batten-1

29/09/2023 07:30
Download PDF File (<1 Mo)

Theranexus announces first half 2023 financial results

28/09/2023 18:00
Download PDF File (<1 Mo)

Theranexus raises around 3.1 million euros in fundraising

11/07/2023 - 07.30 AM CET

Download PDF File (<1Mo)